Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment-Refractory Depression and Suicidal Behavior
Publication: American Journal of Psychiatry
Abstract
Objective:
Treatment-refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. At least 15% of cases of major depressive disorder remain refractory to treatment. The authors previously identified a young adult with treatment-refractory depression and multiple suicide attempts with an associated severe deficiency of CSF tetrahydrobiopterin, a critical cofactor for monoamine neurotransmitter synthesis. Treatment with sapropterin, a tetrahydrobiopterin analogue, led to dramatic and long-lasting remission of depression. This sentinel case led the authors to hypothesize that the incidence of metabolic abnormalities contributing to treatment-refractory depression is underrecognized.
Method:
The authors conducted a case-control, targeted, metabolomic evaluation of 33 adolescent and young adult patients with well-characterized histories of treatment-refractory depression (at least three maximum-dose, adequate-duration medication treatments), and 16 healthy comparison subjects. Plasma, urine, and CSF metabolic profiling were performed by coupled gas chromatography/mass spectrometry and high-performance liquid chromatography electrospray ionization tandem mass spectrometry.
Results:
CSF metabolite abnormalities were identified in 21 of the 33 participants with treatment-refractory depression. Cerebral folate deficiency (N=12) was most common, with normal serum folate levels and low CSF 5-methyltetrahydrofolate (5-MTHF) levels. All patients with cerebral folate deficiency, including one with low CSF levels of 5-MTHF and tetrahydrobiopterin intermediates, showed improvement in depression symptom inventories after treatment with folinic acid; the patient with low tetrahydrobiopterin also received sapropterin. None of the healthy comparison subjects had a metabolite abnormality.
Conclusions:
Examination of metabolic disorders in treatment-refractory depression identified an unexpectedly large proportion of patients with potentially treatable abnormalities. The etiology of these abnormalities remains to be determined.
Major depressive disorder is the second leading cause of disability worldwide and affects an estimated 350 million people (1). Although strides have been made in the treatment of depression, an estimated 15% of depressed individuals do not respond despite adequate pharmacotherapy, psychotherapy, and even ECT (2). Current predictors of treatment response for depression, such as severity, chronicity, and exposure to adverse life events, are nonspecific and without clear therapeutic implications in treatment-refractory depression. The clinical management of treatment-refractory depression has not advanced significantly in the past two decades, and the suicide rate in the United States has been increasing (3). Recent emphasis on treatment-refractory depression has focused on neuromodulatory treatments, such as deep brain stimulation, which, while promising, requires neurosurgical intervention. We propose a novel diagnostic and therapeutic approach to treatment-refractory depression based on a targeted analysis of metabolites in blood, urine, and CSF.
Metabolomics is the study of patterns of metabolic intermediates to characterize dysfunctional metabolic pathways potentially related to symptomatic presentation. This approach has previously contributed to our understanding of the pathophysiology of depression. For example, over three decades ago, decreased CSF levels of 5-hydroxyindoleacetic acid (5-HIAA) in depressed patients were shown to be associated with a markedly elevated risk of suicide (4). This work helped spur the development of selective serotonin reuptake inhibitors, which are now widely used for the treatment of depression (5, 6). In addition, neuropsychiatric symptoms are a common manifestation of many inborn errors of metabolism. Adolescent and adult neuropsychiatric symptoms, possibly caused by metabolic abnormalities, are also a common comorbidity in both primary (7) and secondary forms of mitochondrial dysfunction (8).
We previously reported on the case of a 19-year-old male patient with unremitting treatment-refractory depression and repeated suicide attempts who had deficient CSF levels of tetrahydrobiopterin intermediates and responded to replacement with sapropterin, a tetrahydrobiopterin analogue (9). CSF testing of five additional adolescent patients with treatment-refractory depression revealed that three had low CSF levels of 5-methyltetrahydrofolate (5-MTHF) and normal blood levels of folate, indicating cerebral folate deficiency (10). None of the conventional clinical or research diagnostic or therapeutic approaches would have identified the source of these patients’ difficulties, nor would they have suggested the subsequent successful treatment strategies.
We hypothesized that the incidence of metabolic abnormalities contributing to treatment-refractory depression would be significantly greater than in healthy comparison subjects. Broader identification of such metabolic disorders could transform psychiatric practice, particularly in severe depression, when standard treatments are ineffective. We describe the systematic evaluation of 33 patients with treatment-refractory depression for primary and secondary disorders of CNS metabolism. Targeted studies of CSF and peripheral samples (blood and urine) were utilized to identify patients with abnormalities in the monoamine neurotransmitter synthesis pathway, as well other metabolomic abnormalities leading to apparent isolated CNS dysfunction with depression.
Method
Sample Characteristics
Participants 14–40 years of age with depression that has not responded to at least three maximum-dose medication trials of at least 6 weeks each were recruited by advertisement through the Clinical and Translational Science Institute’s Research Participant Registry at the University of Pittsburgh or by clinical referral. All adult participants provided informed consent; adolescent participants provided informed assent for involvement in the study and parents provided informed consent. We compared this group with young adult healthy comparison subjects who had no personal or first-degree-relative history of psychiatric disorder or suicidal behavior. Adolescent comparison subjects were not included because lumbar puncture confers greater than minimal risk. The study was approved by the Institutional Review Board of the University of Pittsburgh.
A total of 38 patients with treatment-refractory depression and 22 healthy comparison subjects were enrolled. One comparison subject was subsequently excluded after discovery of substance use disorder and suicidal behavior in one of the participant’s parents and another after discovery of self-administration of large quantities of B vitamins. One participant in the depression group was excluded because of a diagnosis of Asperger’s syndrome. Four participants in the depression group and four in the comparison group were excluded because they declined lumbar puncture.
Participants were assessed with a structured psychiatric interview, including the Family Interview for Genetics Studies (11), at the time of referral to characterize depression course, comorbidity, family history, and history of trauma, psychosis, and anxiety. Treatment-refractory depression was confirmed with the Antidepressant Treatment History Questionnaire (12). All participants completed the Beck Depression Inventory (BDI) (13) and the Suicidal Ideation Questionnaire (14), and for adolescents, the Child Depression Rating Scale–Revised (15) was completed on the basis of clinical assessment. Patients remained on their current medications and other treatments during the course of the study.
Study Procedures
The research staff and principal investigator (L.P.) completed structured psychiatric interviews, administered self-report symptom questionnaires, and arranged for study laboratory testing. Assessment consisted of a psychiatric interview, review of records, and self-report instruments at intake to characterize depression course (BDI), suicidal ideation and behavior (Suicidal Ideation Questionnaire, Columbia Suicide History Form [16], and Beck Suicide Ideation Scale [17]), comorbidity (anxiety, psychosis, substance use, attention disorders, assessed with the DSM-5 Level 1 Cross-Cutting Symptom Measure), and family history (Family Interview for Genetic Studies and three-generation pedigree) (11). A neurologic examination was conducted by the principal investigator.
Testing for CNS-specific metabolic abnormalities included 5-methyltetrahydrofolate, tetrahydrobiopterin, neopterin, pyridoxal-5-phosphate, 5-hydroxyindoleacetic acid, homovanillic acid, and amino-adipic semialdehyde. Analysis of blood and CSF began immediately after collection. Plasma and urine testing were performed by the clinical biochemical genetics and clinical chemistry laboratories of University of Pittsburgh Medical Center (UPMC), per their standard protocols, including gas chromatography-mass spectrometry of urine and liquid chromatography tandem mass spectrometry and high-performance liquid chromatography tandem mass spectrometry profiling of blood to examine groups of metabolites known to contribute to depression. Lumbar puncture for CSF collection was performed under fluoroscopic guidance by the Neuroradiology Department at UPMC, and samples were analyzed as for blood and urine by the clinical biochemical genetics and clinical chemistry laboratories of UPMC and Medical Neurogenetics, Inc. (Atlanta). If a specific abnormality was suspected on the basis of the initial testing, the patient was referred to a biochemical geneticist for additional confirmatory testing. Once results of testing became available, a follow-up appointment was scheduled for all participants in the depression group to review results and provide additional referrals if needed. At this appointment, the BDI, the Suicidal Ideation Questionnaire, and the DSM-5 Level 1 Cross-Cutting Symptom Measure were repeated. Participants for whom a novel treatment was available were recontacted at least 6 weeks after start of treatment to determine outcome with repeated administration of the BDI, the Suicidal Ideation Questionnaire, and the DSM-5 Level 1 Cross-Cutting Symptom Measure.
Analyses were conducted in IBM SPSS Statistics, version 21 (IBM, Armonk, N.Y.). We employed independent t tests to examine the differences between the depression and healthy comparison groups in depression severity (BDI), suicidal ideation (Suicidal Ideation Questionnaire), and age. A chi-square goodness-of-fit test was used to compare the sex distribution of each group. Because of the small number of participants who were assessed before and after intervention (N=10), Wilcoxon signed-ranks tests were performed between pre- and posttreatment BDI and Suicidal Ideation Questionnaire scores among the participants who were deficient in cerebral folate.
Results
The treatment-refractory depression group (N=33) and the healthy comparison group (N=16) were similar with respect to age, sex, and ethnicity (Table 1).
| Characteristic | Depression Group (N=33) | Comparison Group (N=16) | ||
|---|---|---|---|---|
| Mean | SD | Mean | SD | |
| Age (years) | 26.21 | 7.63 | 26.12 | 6.11 |
| N | % | N | % | |
| Female | 25 | 76 | 9 | 56 |
| Race | ||||
| African American | 1 | 3 | 2 | 13 |
| Asian | 0 | 0 | 4 | 25 |
| Caucasian | 30 | 91 | 9 | 56 |
| Multiple races | 2 | 6 | 1 | 6 |
| Hispanic | 2 | 6 | 0 | 0 |
Characterization of Depression
The characteristics of each of the 33 patients in the treatment-refractory depression group are summarized in Table 2. Participants reported long-standing unremitting or recurrent depression, with a mean of 5.1 episodes (SD=15.98) and a mean longest duration of episode without symptom remission of 453.9 weeks (SD=386.51). The mean age at onset of depressive symptoms in the depression group was 12.4 years (SD=5.05). The mean BDI score was much higher in the depression group than in the healthy comparison group (mean=29.2 [SD=8.4] compared with mean=0.6 [SD=1.2]; t=13.60, df=47, p<0.001). The depression group also had a much higher mean Suicidal Ideation Questionnaire score than the comparison group (mean=36.39 [SD=21.40] compared with mean=1.18 [SD=1.08]; t=6.57, df=47, p<0.001). Half of the participants in the depression group (N=17) reported a history of at least one suicide attempt.
| Patient | Depressed Episodesb (N) | Age at Onset of Depressionb (years) | Duration of Longest Episodeb (weeks) | Suicide Attemptsb (N) | Comorbid Disorders | Family History of Major Depression | Family History of Bipolar Disorderc | Medication Trialsd (N) |
|---|---|---|---|---|---|---|---|---|
| Cerebral folate deficiency | ||||||||
| 1 | 2 | 15 | 600 | 1 | PTSD, anxiety | Yes | Yes | 6 |
| 2 | 1 | 9 | 468 | 1 | Anxiety | Yes | No | >10 |
| 3 | 2 | 12 | 468 | 5 | PTSD, anxiety, ADHD | Yes | No | 8 |
| 4 | 1 | 26 | 208 | 4 | PTSD | No | Yes | 4 |
| 5 | >100 | 9 | 50 | 0 | PTSD, ADHD, substance use disorder | Yes | Yes | 9 |
| 6 | 2 | 16 | 312 | 0 | Substance use disorder | Yes | No | 4 |
| 7 | 2 | 12 | 72 | 0 | Anxiety | No | No | 4 |
| 8 | 2 | 13 | 156 | 5 | PTSD | Yes | No | >10 |
| 9 | 1 | 20 | 28 | 1 | None | No | No | 3 |
| 10 | 1 | 4 | 1,300 | 3 | PTSD, anxiety | Yes | No | 9 |
| 11 | 1 | 11 | 362 | 0 | PTSD | Yes | Yes | 3 |
| 12 | 90 | 14 | 12 | 0 | Substance use disorder | No | Yes | 3 |
| Other metabolic disorders | ||||||||
| 13 | 1 | 5 | 1,092 | 0 | OCD, PTSD | Yes | No | 4 |
| 14 | 2 | 5 | 468 | 0 | Anxiety | Yes | No | 5 |
| 15 | 1 | 12 | 1,352 | 10 | PTSD, psychosis not otherwise specified | Yes | Yes | >10 |
| 16 | 2 | 13 | 364 | 0 | Anxiety | Yes | No | 6 |
| 17 | >100 | 21 | 104 | 1 | Anxiety | No | No | >10 |
| 18 | 1 | 17 | 1,092 | 0 | PTSD | Yes | Yes | >10 |
| 19 | 1 | 13 | 364 | 1 | Anxiety, ADHD | Yes | No | 9 |
| 20 | 2 | 11 | 208 | 0 | Anxiety, OCD | No | No | 4 |
| 21 | 15 | 8 | 12 | 2 | Anxiety | Yes | Yes | 10 |
| No metabolic disorder | ||||||||
| 22 | 6 | 9 | 468 | 1 | PTSD, anxiety | Yes | No | 6 |
| 23 | 1 | 12 | 884 | 2 | None | Yes | Yes | 8 |
| 24 | 5 | 9 | 728 | 0 | None | Yes | No | 7 |
| 25 | 1 | 23 | 572 | 0 | Anxiety | No | No | 10 |
| 26 | 2 | 6 | 364 | 0 | None | Yes | No | 8 |
| 27 | 1 | 10 | 416 | 2 | Anxiety | Yes | No | 6 |
| 28 | 1 | 13 | 364 | 4 | PTSD, psychosis | Yes | No | >10 |
| 29 | 1 | 14 | 1,042 | 0 | PTSD, anxiety, substance use disorder | Yes | Yes | 7 |
| 30 | 1 | 7 | 780 | 0 | None | Yes | No | 4 |
| 31 | 4 | 13 | 36 | 1 | Anxiety | Yes | No | 4 |
| 32 | 1 | 12 | 208 | 1 | Anxiety | No | No | 5 |
| 33 | 5 | 16 | 24 | 0 | None | Yes | No | >10 |
a
For all patients, level of impairment on the Family Interview for Genetic Studies was rated 2 (“incapacitated”), except patient 29, for whom it was rated 1 (“impaired”). ADHD=attention deficit hyperactivity disorder; OCD=obsessive-compulsive disorder; PTSD=posttraumatic stress disorder.
b
Assessed from Family Interview for Genetic Studies reports.
c
Only four patients had a personal history of bipolar disorder: patients 5, 15, 17, and 18.
d
Five patients had also received ECT: patients 2, 4, 11, 16, and 28.
On the Family Interview for Genetic Studies, 88% of participants in the depression group had a positive family history in at least one first-degree relative for any disorder, 82% for depression, and 24% for suicide attempts. By definition, the healthy comparison subjects had no personal or first-degree-relative history of psychiatric disorders or suicidal behavior. On neurologic examination, no abnormalities were noted in either of the two groups, with the exception of one adolescent in the depression group who had a benign fine hand tremor.
Metabolic Clinical Studies
We identified evidence of metabolite abnormalities in 21 of the 33 participants in the depression group (Tables 3 and 4). Cerebral folate deficiency (CFD), a metabolic abnormality in which the serum folate level is normal but the CSF 5-MTHF level is low (<40 nmol/L), was the most common metabolic abnormality identified, present in 12 participants (36%). One participant with CFD also had low CSF levels of tetrahydrobiopterin metabolites, as seen in our previously published case of a patient who responded to treatment with sapropterin (9). Abnormalities were identified in nine additional participants: five with an acylcarnitine profile abnormality, one with a low guanidinoacetate level and a creatine/creatinine ratio consistent with a creatine synthesis deficit, one with Fabry’s disease, one with a 20p12.1 microdeletion, and one with a 15q13.3 microduplication on microarray analysis.
| Patient | Metabolic Findings | CSF 5-MTHF Level (nmol/L) | Serum Folate Level (ng/mL) | Initial Visit | Posttreatment Visit | Interval From Initial to Posttreatment Self-Report (weeks) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Psychiatric Medications | SIQ Score | BDI Score | Psychiatric Medications | SIQ Score | BDI Score | |||||
| 1 | Low CSF 5-MTHF | 40 | 6.1 | None | 13 | 22 | Folinic acid | 8 | 15 | 6 |
| 2 | Low CSF 5-MTHF | 39 | >20.0 | Citalopram, risperidone, amitriptyline, trazodone | 36 | 25 | Folinic acid, amitriptyline, trazodone, 5-HTP, carbidopa | 17 | 14 | 36 |
| 3 | Low CSF 5-MTHF | 37 | >20.0 | Trazodone | 61 | 29 | Folinic acid, trazodone | 45 | 29 | 8 |
| 4 | Low CSF 5-MTHF | 39 | 12.2 | Zolpidem, vilazodone | 70 | 37 | Folinic acid, zolpidem, vilazodone | 58 | 36 | 11 |
| 5 | Low CSF 5-MTHF | 36 | >20.0 | Baclofen, gabapentin, tramadol | 23 | 33 | Folinic acid, baclofen, gabapentin, tramadol, lithium carbonate, dextroamphetamine | 18 | 17 | 20 |
| 6 | Low CSF 5-MTHF | 15 | >20.0 | Fluoxetine | 14 | 24 | Folinic acid, fluoxetine | 13 | 13 | 15 |
| 7 | Low CSF 5-MTHF | 14 | 18.3 | Sertraline, carbidopa, lamotrigine | 41 | 28 | Folinic acid, sertraline, carbidopa, lamotrigine | 20 | 16 | 7 |
| 8 | Low CSF 5-MTHF | 35 | 14.4 | Sertraline | 67 | 43 | Folinic acid, sertraline | 15 | 0 | 79 |
| 9 | Low CSF 5-MTHF | 37 | >20.0 | Bupropion | 20 | 20 | Lost to follow-up | |||
| 10 | Low CSF 5-MTHF | 40 | 17.6 | Lamotrigine, escitalopram, clonazepam, trazodone | 53 | 31 | Nonadherent with folinic acid | |||
| 11 | Low CSF 5-MTHF, low tetrahydrobiopterin | 31 | >20.0 | Sertraline, escitalopram, lisdexamfetamine, hydroxyzine | 47 | 40 | Folinic acid, 5-HTP, carbidopa, sapropterin, lisdexamfetamine, hydroxyzine | 33 | 35 | 52 |
| 12 | Low CSF 5-MTHF, abnormal acylcarnitine profile | 36 | >20.0 | None | 8 | 25 | Folinic acid | 4 | 21 | 10 |
a
5-HTP=5-hydroxytryptophan; 5-MTHF=5-methyltetrahydrofolate; BDI=Beck Depression Inventory; SIQ=Suicide Ideation Questionnaire.
| Patient | Metabolic Findings | CSF 5-MTHF Level (nmol/L) | Serum Folate Level (ng/mL) | Initial Visit | ||
|---|---|---|---|---|---|---|
| Psychiatric Medications | SIQ Score | BDI Score | ||||
| Other metabolic disorders | ||||||
| 13 | Abnormal acylcarnitine profile | 68 | 17.6 | Citalopram, melatonin | 53 | 37 |
| 14 | Abnormal creatine/guanidinoacetate ratio | 55 | 13.4 | Aripiprazole, diazepam, methylphenidate, lamotrigine, bupropion | 15 | 38 |
| 15 | Abnormal acylcarnitine profile | 60 | >20.0 | Lamotrigine, clonazepam, fluoxetine | 33 | 35 |
| 16 | Abnormal acylcarnitine profile | 109 | 19.3 | Levothyroxine sodium, lorazepam, sertraline, lurasidone, hydroxyzine | 36 | 29 |
| 17 | Fabry’s disease | 77 | 14.5 | Lithium carbonate, trazodone | 15 | 19 |
| 18 | Abnormal acylcarnitine profile | 92 | 10.2 | Gabapentin, lithium carbonate, lamotrigine, clonazepam, olanzapine | 32 | 32 |
| 19 | Abnormal acylcarnitine profile, abnormal creatine/guanidinoacetate ratio | 59 | >20.0 | Nortriptyline, sertraline | 72 | 32 |
| 20 | 20p12.1 microdeletion on chromosome analysis | 67 | >20.0 | Venlafaxine, fluvoxamine | 22 | 24 |
| 21 | 15q13.3 microduplication on chromosome analysis | 45 | 16.6 | Desvenlafaxine, divalproex sodium, aripiprazole | 17 | 26 |
| No metabolic disorder | ||||||
| 22 | 60 | 17.5 | Imipramine, venlafaxine, quetiapine fumarate | 37 | 41 | |
| 23 | 46 | >20.0 | Sertraline, quetiapine fumarate | 59 | 33 | |
| 24 | 54 | >20.0 | Amitriptyline, citalopram, levothyroxine sodium | 12 | 12 | |
| 25 | 58 | 9.8 | Bupropion, vilazodone, temazepam, clonazepam | 11 | 19 | |
| 26 | 49 | 10.3 | Lamotrigine, melatonin | 22 | 25 | |
| 27 | 52 | 17.6 | None | 41 | 22 | |
| 28 | 59 | >20.0 | Clozapine | 88 | 49 | |
| 29 | 53 | >20.0 | Venlafaxine | 11 | 17 | |
| 30 | 59 | 18.6 | Clonazepam | 55 | 39 | |
| 31 | 51 | >20.0 | None | 20 | 22 | |
| 32 | 78 | >20.0 | Fluoxetine, lamotrigine, mirtazapine | 48 | 24 | |
| 33 | 48 | >20.0 | Lisdexamfetamine, trazodone, levothyroxine sodium | 49 | 30 | |
a
5-MTHF=5-methyltetrahydrofolate; BDI=Beck Depression Inventory; SIQ=Suicide Ideation Questionnaire.
Treatment Outcomes
Of the 12 patients with CFD, all were treated with folinic acid (1–2 mg/kg per day) for at least 6 weeks (range 6–79 weeks), while continuing their pre-evaluation treatment regimen. Ten of the 12 patients showed reductions in symptom inventory scores at follow-up. One patient was lost to follow-up, and one was nonadherent with the folinic acid treatment. Eight participants with CFD who completed follow-up did not have any comorbid biochemical findings. Of these, four had reductions in BDI score to below the threshold for depression. Five of the eight patients met threshold scores for suicidal ideation on the Suicidal Ideation Questionnaire at intake, and three of these five had reductions in suicidal ideation scores to below threshold after treatment. One patient with CFD was also treated with sapropterin (20 mg/kg per day) for low CSF tetrahydrobiopterin levels. FOLR1 gene sequencing was conducted for eight of the 12 patients, and no sequence abnormalities were identified. In patients with CFD, the mean BDI score decreased from 30.6 (SD=7.29) to 11.0 (SD=11.03) (Wilcoxon signed ranks test, Z=2.0, p<0.022). The mean Suicidal Ideation Questionnaire score decreased from 38.0 (SD=23.13) to 23.1 (SD=17.09), although the change was not statistically significant (Table 3, Figure 1).
FIGURE 1. Symptom Inventory Outcomes in Patients With Treatment-Refractory Depression and Cerebral Folate Deficiency (CFD), Before and After Treatment With Folinic Acid (N=10)a
a Follow-up interval ranged from 6 to 79 weeks. The mean score on the Suicide Ideation Questionnaire was 38.0 (SD=23.13) at baseline and 23.1 (SD=17.09) at follow-up (Z=1.24, p=0.107). The mean score on the Beck Depression Inventory was 30.6 (SD=7.3) at baseline and 19.6 (SD=11.04) at follow-up (Z=2.0, p=0.022).
Discussion
To our knowledge, this CNS-specific metabolomic survey is the first to systematically evaluate abnormalities of neurotransmitter, vitamin, pterin, and energy metabolism in peripheral and CSF samples from patients with isolated psychiatric symptoms in the absence of primary neurologic symptoms. It was spurred by our initial identification of a young man with a severe deficiency of CSF tetrahydrobiopterin who responded to treatment with sapropterin, followed by our discovery of CFD in three of five additional patients (9). In this case-control study of 33 individuals with treatment-refractory depression, 21 had metabolite abnormalities. Results were determined based on established clinical norms for all tests reported.
Twelve patients had CFD, and in 10 of these patients BDI and Suicidal Ideation Questionnaire scores were reduced after treatment with folinic acid; of the remaining two patients, one was nonadherent with folinic acid treatment and the other was lost to follow-up. Half of the eight patients who completed follow-up and did not have a comorbid identified metabolic abnormality had reductions in BDI score to below the threshold for depression. In all cases, patients had normal serum metabolites associated with folate pathways and therefore would have eluded conventional diagnostic approaches without a more comprehensive evaluation.
It should be noted that the abnormalities identified may be due either to a primary genetic disorder in a metabolic pathway or a secondary abnormality of indirect etiology (e.g., injury to the CNS from infection, autoimmune disease, asphyxia, or epilepsy), typically with other obvious systemic manifestations (18). The abnormalities identified could also be sequelae of unremitting depression. CFD is a CNS-specific syndrome characterized by low CSF 5-MTHF levels and normal plasma folate levels (19, 20). It can be caused primarily by mutations in the cerebral folate receptor gene (FOLR1) but can be secondarily reduced in any metabolic defect that increases use of methyl groups, or by changes in transport across the blood-brain barrier. FOLR1 gene sequencing was normal in the first eight patients with identified CFD. Secondary CFD is also seen in disorders of the mitochondrial respiratory chain, such as Alpers’ syndrome (21), Kearns-Sayre syndrome (22), and others (23). Folate is involved in nearly 100 metabolic reactions (24), including the purine synthetic pathway, contributing to impaired tetrahydrobiopterin, serotonin, norepinephrine, and dopamine synthesis, and thus polygenic effects due to the accumulation of mutations in multiple genes may play a role in this population (25, 26).
The findings in this patient population are different from those in reports of empirical treatment with l-methylfolate (27–30). Adjunctive treatment with l-methylfolate may improve depressive symptoms because of its role as a cofactor in monoamine metabolism (31). This is different from our findings in CFD (18). Also, l-methylfolate is most helpful in those with the MTHFR polymorphism, which was negative in the eight patients with CFD in whom we conducted gene testing. We continue to work to understand the biologic mechanism of our biochemical findings. It is clear that treatment with l-methylfolate is not sufficient in these individuals, because of a deficit earlier in the folate metabolic pathway that produces bioactive metabolites. Furthermore, the administration of l-methylfolate will falsely correct the CSF test to identify these individuals. While empirical treatment with folinic acid may seem appealing, this again is problematic with our current understanding. After folinic acid administration, definitive testing cannot be conducted, and the full effects of treatment with folinic acid in an individual with CFD occur over years. This time frame is due to neuronal turnover and growth in the setting of availability of active folate metabolites needed for appropriate white matter structure. We cannot determine whether the metabolite abnormalities are primary or secondary. However, our patients had no other overt clinical disease, and thus secondary deficiencies related to other systemic conditions are unlikely. Applications of next-generation sequencing technologies (i.e., whole exome or genome sequencing) on a focused, homogeneous patient population with treatment-refractory depression will provide further insight into genetic components of the metabolic findings in our patients. After further evaluation and characterization of a larger population of patients, animal models of biochemical abnormalities will be an important next step.
Although the majority of patients in this study were recruited by advertisement through a research registry, four participants were clinically referred, and the possibility of an ascertainment bias cannot be excluded. This was a relatively small sample of mostly Caucasian patients, and the treatment component of the study was an open trial. Continued treatment as usual resulted in medication changes during the course of the study, meaning that in three cases of CFD, there were concomitant medication changes in addition to folinic acid supplementation. Preliminary experience with treatment has been promising; however, long-term outcomes remain to be determined.
CSF testing is required to determine the presence of CFD and need for treatment. Review of the CSF metabolic profile directs the diagnosis and avoids missing other metabolic disorders that may be present. l-Methylfolate (5-l-methyltetrahydrofolate) is the treatment specific to methylenetetrahydrofolate deficiency (32), but in the majority of cases, folinic acid is preferable because of its superior stability and lower costs when compared with l-methylfolate. Dihydrofolate reductase converts folic acid to dihydrofolate and then to tetrahydrofolate (Figure 2). Folinic acid (5-formyl-tetrahydrofolate) is converted to 5-,10-methenyltetrahydrofolate, then 5-,10-methylenetetrahydrofolate, and eventually to 5-MTHF. Folinic acid therefore allows the availability of active metabolites in the folate pathway in individuals with CFD that is not caused by methylenetetrahydrofolate deficiency. Furthermore, folinic acid has therapeutic effect in the setting of folate receptor autoantibodies, although there is controversy surrounding the assessment of these autoantibodies (33).
FIGURE 2. Summary of the Folate Pathwaya
a Folinic acid (5-formyl-THF) enters the pathway without the action of DHFR and contributes active metabolites. 5-Methyl-THF is a distal metabolite. DHFR=dihydrofolate reductase; DHF=dihydrofolate; dTMP=deoxy-thymidine phosphate; dUMP=deoxy-uridine phosphate; NAD=nicotinamide adenine dinucleotide; NADP=nicotinamide adenine dinucleotide phosphate; NADPH=nicotinamide adenine dinucleotide phosphate, reduced; THF=tetrahydrofolate.
Folinic acid should be given by prescription. Dosages of 1–2 mg/kg per day may be administered with prescription-strength folinic acid. Treatment with either folinic acid or l-methylfolate will preclude testing after administration because they correct deficient CSF 5-MTHF levels. A clinical response should be expected in patients with treatment-refractory depression and low CSF 5-MTHF levels. Experience with more severe neurologic disorder associated with CFD (34) indicates that the response may take several months, but the full effect of treatment may take 1–3 years. This may be related to neuronal growth and turnover in an environment in which folate metabolites are newly available. Folic acid is not recommended because of the potentially low activity of dihydrofolate reductase in CFD and because of its tight binding to folate receptor alpha, which results in reduced cerebral transport of 5-MTHF. Folinic acid treatment in our patients did have some side effects (facial flushing and initial anxiety). It is important to note that vitamin B12 acts as a cofactor in this pathway. Blood folate and B12 levels should be evaluated in all patients with treatment-refractory depression. The best option for patients with treatment-refractory depression for whom metabolic disorder is suspected is consultation with a biochemical geneticist.
Our findings indicate a need for further evaluation of the role of neurometabolic abnormalities in treatment-refractory depression. The remarkably high incidence of actionable abnormalities and some evidence of symptom improvement with treatment strongly support the need for larger studies. Historically, a diagnosis of a metabolic disorder has been considered in the context of a family history of a known disorder or symptoms that are exacerbated by significant physiologic stresses (e.g., fever, fasting, surgeries), especially with multisystem involvement (35), neither of which was present in our patient population. Our findings, if replicated, suggest that neurometabolic disorders may contribute to treatment-refractory psychiatric disorders even without other systemic illness. An important question is whether early identification and treatment of an underlying metabolic abnormality early in the course of psychiatric illness could prevent long-term emotional and cognitive complications. If these findings are replicated, they suggest that the identification of new inborn errors of metabolism or secondary disorders of metabolism contributing to psychiatric illness may allow repurposing of currently approved orphan drugs.
Acknowledgments
The authors thank the participants who made this research possible, and they thank Katherine Wisner, M.D., and Vishwajit Nimgaonkar, M.D., Ph.D., for their review of the manuscript.
References
1.
Souery D, Papakostas GI, Trivedi MH: Treatment-resistant depression. J Clin Psychiatry 2006; 67(suppl 6):16–22
2.
The burden of depression. Nature 2014; 515:163
3.
Centers for Disease Control and Prevention: Centers for Disease Control and Prevention Data and Statistical Fatal Injury Report, 2013
4.
Asberg M, Träskman L, Thorén P: 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry 1976; 33:1193–1197
5.
Axelrod J, Forslund K: Biogenic amines and their impact in psychiatry. Semin Psychiatry 1972; 4:199–210
6.
Asberg M, Forslund K: Neurobiological aspects of suicidal behavior. Int Rev Psychiatr 2000; 12:62–74
7.
Anglin RE, Garside SL, Tarnopolsky MA, et al: The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. J Clin Psychiatry 2012; 73:506–512
8.
Morris G, Berk M: The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med 2015; 13:68
9.
Pan L, McKain BW, Madan-Khetarpal S, et al: GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour. BMJ Case Rep 2011;
10.
Hyland K, Shoffner J, Heales SJ: Cerebral folate deficiency. J Inherit Metab Dis 2010; 33:563–570
11.
NIMH Genetics Initiative: Family Interview for Genetic Studies (FIGS). Rockville, Md, NIMH, 1992
12.
Fava M: Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53:649–659
13.
Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561–571
14.
Reynolds WM: Suicidal Ideation Questionnaire: Professional Manual. Odessa, Fla, Psychological Assessment Resources, 1987
15.
Poznanski EO, Mokros HB: Children’s Depression Rating Scale, Revised (CDRS-R). Los Angeles, Western Psychological Services, 1996
16.
Posner K, Oquendo MA, Gould M, et al: Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164:1035–1043
17.
Beck AT, Schuyler D, Herman I: Development of suicidal intent scales, in The Prediction of Suicide. Edited by Beck AT, Resnick HLP, Lettieri DJ. Bowie, Md, Charles Press, 1974, pp 45–56
18.
Serrano M, Pérez-Dueñas B, Montoya J, et al: Genetic causes of cerebral folate deficiency: clinical, biochemical, and therapeutic aspects. Drug Discov Today 2012; 17:1299–1306
19.
Pan L, Vockley J: Neuropsychiatric symptoms in inborn errors of metabolism: incorporation of genomic and metabolomic analysis into therapeutics and prevention. Curr Genet Med Rep 2013; 1:65–70
20.
Sedel F: Cerebral Folate Deficiency. Presentation at Behavioural and Psychiatric Aspects of Inborn Errors of Metabolism. Paris, Orphan Europe Academy, 2013
21.
Cohen BH, Chinnery PF, Copeland WC: POLG-related disorders, in GeneReviews. Edited by Pagon RA, Adam MP, Ardinger HH, et al. Seattle, University of Washington, 2010. [Internet]
22.
Quijada-Fraile P, O’Callaghan M, Martín-Hernández E, et al: Follow-up of folinic acid supplementation for patients with cerebral folate deficiency and Kearns-Sayre syndrome. Orphanet J Rare Dis 2014; 9:217
23.
Garcia-Cazorla A, Quadros EV, Nascimento A, et al: Mitochondrial diseases associated with cerebral folate deficiency. Neurology 2008; 70:1360–1362
24.
Bottiglieri T, Hyland K, Laundy M, et al: Folate deficiency, biopterin, and monoamine metabolism in depression. Psychol Med 1992; 22:871–876
25.
Vockley J, Rinaldo P, Bennett MJ, et al: Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol Genet Metab 2000; 71:10–18
26.
Trefz F, Maillot F, Motzfeldt K, et al: Adult phenylketonuria outcome and management. Mol Genet Metab 2011; 104(suppl):S26–S30
27.
Fava M, Mischoulon D: Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry 2009; 70(suppl 5):12–17
28.
Papakostas GI, Shelton RC, Zajecka JM, et al: L-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012; 169:1267–1274
29.
Jain R, Jackson WC: Beyond the resistance: how novel neurobiological understandings of depression may lead to advanced treatment strategies. J Clin Psychiatry 2012; 73:e30
30.
Papakostas GI, Shelton RC, Zajecka JM, et al: Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry 2014; 75:855–863
31.
Ramaekers VT, Blau N: Cerebral folate deficiency. Dev Med Child Neurol 2004; 46:843–851
32.
Knowles L, Morris AA, Walter JH: Treatment with mefolinate (5-methyltetrahydrofolate), but not folic acid or folinic acid, leads to measurable 5-methyltetrahydrofolate in cerebrospinal fluid in methylenetetrahydrofolate reductase deficiency. JIMD Rep (Epub ahead of print, Feb 23, 2016)
33.
Ramaekers VT, Thöny B, Sequeira JM, et al: Folinic acid treatment for schizophrenia associated with folate receptor autoantibodies. Mol Genet Metab 2014; 113:307–314
34.
Molero-Luis M, Serrano M, O’Callaghan MM, et al: Clinical, etiological, and therapeutic aspects of cerebral folate deficiency. Expert Rev Neurother 2015; 15:793–802
35.
Walterfang M, Bonnot O, Mocellin R, et al: The neuropsychiatry of inborn errors of metabolism. J Inherit Metab Dis 2013; 36:687–702
Information & Authors
Information
Published In
History
Received: 29 November 2015
Revision received: 11 March 2016
Accepted: 20 May 2016
Published online: 13 August 2016
Published in print: January 01, 2017
Authors
Funding Information
Children's Hospital of Pittsburgh Foundation
American Foundation for Suicide Prevention10.13039/100001455: Standard Research Grant
Brain and Behavior Research Foundation10.13039/100000874: NARSAD Young Investigator Award
Clinical and Translational Research Institute University of Pittsburgh: NIH UL1 RR024153 and UL1TR000005.
Supported by the Brain and Behavior Research Foundation NARSAD Young Investigator Award; and by the Clinical and Translational Science Institute, University of Pittsburgh, through NIH grants UL1 RR024153 and UL1 TR000005. Ongoing research is supported by the American Foundation for Suicide Prevention Standard Research Award, the Children’s Hospital of Pittsburgh Foundation, and departmental funding supported by David A. Brent, M.D., Jerry Vockley, M.D., Ph.D., and David A. Lewis, M.D.Dr. Hyland is executive vice president of Medical Neurogenetics Laboratories. Dr. Finegold is founder of Diavacs and Personalized Genomics Laboratories. Dr. Brent receives research support from NIMH, royalties from Guilford Press, royalties from the electronic self-rated version of the Columbia Suicide Severity Rating Scale from ERT, Inc., honoraria for performing duties as an UpToDate Psychiatry section editor, and consulting fees from Healthwise. The other authors report no financial relationships with commercial interests.Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).